Accounting Haisco licenses drug to US venture for $1.5bnBy AdminBitAugust 26, 20260 The deal is valued at over $1.5 billion and will grant Sentivera global rights to develop, manufacture, and commercialize a preclinical drug targeting type 2 inflammatory diseases, excluding Greater China.
